Drug Profile


Alternative Names: Androgel-DHT; Testosterone gel

Latest Information Update: 04 Dec 2006

Price : $50

At a glance

  • Originator Unknown
  • Developer Besins Healthcare
  • Class Androstanols; Testosterone congeners
  • Mechanism of Action Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Marketed Hypogonadism
  • Discontinued Cachexia

Most Recent Events

  • 04 Dec 2006 Discontinued - Phase-III for Cachexia in USA (Topical)
  • 01 Feb 2001 A study has been added to the Men's Health therapeutic trials section
  • 20 Jan 2001 Launched for Hypogonadism in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top